She Miaorong, Jim Yeung Sai-Ching
Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Cancer Lett. 2006 Jul 18;238(2):197-201. doi: 10.1016/j.canlet.2005.07.012. Epub 2005 Sep 8.
We previously showed that the in vivo anticancer effects of a combination of manumycin (a farnesyltransferase inhibitor) and paclitaxel (a microtubule inhibitor) against anaplastic thyroid carcinoma (ATC) were partially due to inhibition of angiogenesis. In this study, we investigated the effect of adding minocycline (a matrix metalloproteinase inhibitor) to manumycin and paclitaxel against human ATC cells xenografted in nude mice. The triple-drug combination resulted in the lowest average tumor growth rate, and it conferred significantly better survival than manumycin alone, paclitaxel alone, or manumycin plus paclitaxel. In conclusion, this novel combination deserves further investigation in the treatment of ATC.
我们之前表明，法尼基转移酶抑制剂马尼霉素与微管抑制剂紫杉醇联合使用对间变性甲状腺癌（ATC）的体内抗癌作用部分归因于对血管生成的抑制。在本研究中，我们研究了在马尼霉素和紫杉醇中加入米诺环素（一种基质金属蛋白酶抑制剂）对裸鼠体内移植的人ATC细胞的影响。三联药物组合导致平均肿瘤生长速率最低，并且与单独使用马尼霉素、单独使用紫杉醇或马尼霉素加紫杉醇相比，其显著提高了生存率。总之，这种新型组合在ATC治疗中值得进一步研究。
